Automated solutions to spearhead the global fight against cancer

Cancer remains a growing global healthcare issue, and precision medicine is revolutionizing research, diagnostics and treatment in oncology. A major driver for this progress is the rapid advancement in genome sequencing technologies, which continue to reveal genomic mutations that can be targeted by tailored therapies. A growing body of knowledge is helping clinicians to further understand diagnostic markers and disease pathways underlying many cancers, leading to new methods for earlier diagnosis and advanced, personalized treatments.

State-of-the-art sequencing instruments are required to perform the complex assays that are fundamental to the development of precision oncology, and sequencing laboratories are calling for innovative technologies that can meet the rising throughput demands and aid the interpretation of vast quantities of data. This is essential to fully understand cancer mechanisms and, ultimately, develop more effective and timely treatments to improve patient outcomes.

The automation of sequencing workflows for higher throughput and greater reliability is undoubtedly increasing, allowing libraries to be generated overnight – with no requirement for manual input – ready for analysis the next morning.

Tecan has been a pioneer and market leader in laboratory automation for more than 40 years and offers a comprehensive and expanding range of innovative products and solutions. These technologies can be used to automate every stage of the NGS workflow, from liquid biopsy and tissue extraction to the preparation of RNA and DNA-based NGS libraries for sequencing in research and clinical settings.

With the acquisition of Paramit Corporation in 2021, we are ideally placed to expand our portfolio of complementary products for research, diagnostics and the medical field, now truly enabling us to scale oncology innovations from life sciences research to the clinic. Together, we offer a global development, production and support infrastructure that provides unparalleled support to our customers, and we contribute to better management of oncology and other diseases from basic research and early prevention all the way to late-stage treatment.

The translation of insights from technologies like sequencing into the clinical space will only increase in the coming years, and Tecan is excited to play a significant role in turning scientific breakthroughs in cancer research into practical healthcare solutions.

Achim von Leoprechting CEO